Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo.

Finch DK, Midha A, Buchanan CL, Cochrane D, Craggs RI, Cruwys S, Grahames C, Kolbeck R, Lowe DC, Maltby J, Pattison DV, Vousden KA, Ward A, Sleeman MA, Mallinder PR.

Br J Pharmacol. 2011 Jan;162(2):480-90. doi: 10.1111/j.1476-5381.2010.01061.x.

2.

E. coli expression and purification of human and cynomolgus IL-15.

Ward A, Anderson M, Craggs RI, Maltby J, Grahames C, Davies RA, Finch D, Pattison D, Oakes H, Mallinder PR.

Protein Expr Purif. 2009 Nov;68(1):42-8. doi: 10.1016/j.pep.2009.05.004. Epub 2009 May 10.

PMID:
19435602
3.

Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.

Nicholls DJ, Tomkinson NP, Wiley KE, Brammall A, Bowers L, Grahames C, Gaw A, Meghani P, Shelton P, Wright TJ, Mallinder PR.

Mol Pharmacol. 2008 Nov;74(5):1193-202. doi: 10.1124/mol.107.044610. Epub 2008 Aug 1.

PMID:
18676678
4.

Evaluation of a series of bicyclic CXCR2 antagonists.

Walters I, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, David Nicholls, David Robinson.

Bioorg Med Chem Lett. 2008 Jan 15;18(2):798-803.

PMID:
18240390
5.

Disruption of the P2X7 purinoceptor gene abolishes chronic inflammatory and neuropathic pain.

Chessell IP, Hatcher JP, Bountra C, Michel AD, Hughes JP, Green P, Egerton J, Murfin M, Richardson J, Peck WL, Grahames CB, Casula MA, Yiangou Y, Birch R, Anand P, Buell GN.

Pain. 2005 Apr;114(3):386-96.

PMID:
15777864
6.

A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.

Elagoz A, Henderson D, Babu PS, Salter S, Grahames C, Bowers L, Roy MO, Laplante P, Grazzini E, Ahmad S, Lembo PM.

Br J Pharmacol. 2004 Jan;141(1):37-46. Epub 2003 Dec 8.

7.

Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes.

Grahames CB, Michel AD, Chessell IP, Humphrey PP.

Br J Pharmacol. 1999 Aug;127(8):1915-21.

8.

Blockade of human P2X7 receptor function with a monoclonal antibody.

Buell G, Chessell IP, Michel AD, Collo G, Salazzo M, Herren S, Gretener D, Grahames C, Kaur R, Kosco-Vilbois MH, Humphrey PP.

Blood. 1998 Nov 15;92(10):3521-8.

9.

Functional characterisation of P2 purinoceptors in PC12 cells by measurement of radiolabelled calcium influx.

Michel AD, Grahames CB, Humphrey PP.

Naunyn Schmiedebergs Arch Pharmacol. 1996 Nov;354(5):562-71.

PMID:
8938653
10.

Localization of P2X purinoceptor transcripts in the rat nervous system.

Kidd EJ, Grahames CB, Simon J, Michel AD, Barnard EA, Humphrey PP.

Mol Pharmacol. 1995 Oct;48(4):569-73.

PMID:
7476880
11.

The selective P2X purinoceptor agonist, beta,gamma-methylene-L-adenosine 5'-triphosphate, discriminates between smooth muscle and neuronal P2X purinoceptors.

Trezise DJ, Michel AD, Grahames CB, Khakh BS, Surprenant A, Humphrey PP.

Naunyn Schmiedebergs Arch Pharmacol. 1995 Jun;351(6):603-9.

PMID:
7675118

Supplemental Content

Loading ...
Support Center